# Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

> **NCT05721729** · PHASE2 · COMPLETED · sponsor: **Vogenx, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Postbariatric Hypoglycemia

## Interventions

- **DRUG:** Mizagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05721729
- **Lead sponsor:** Vogenx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-23
- **Primary completion:** 2024-05-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05721729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05721729, "Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05721729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*